علاج الكارسينويد الثيموسي النقيلي المتقدم: النمط الكلاسيكي، إيجابي SRI، بطيء التقدم

References

DOI: 10.1016/j.annonc.2021.01.003

• SSAs are recommended first-line treatment in patients with TC and/or slowly progressing advanced SRI-positive LC and ThC [IV, C]
• PRRT (based on positive uptake at SRI on all RECIST-evaluable targets) as alternative second-line (in case of uncontrolled CS) or mainly third-line therapy (beyond SSAs and or everolimus) in morphologically progressive or high tumour burden advanced LC and ThCs is recommended [IV, B]
• IFN-a as a potential second-line (in case of uncontrolled CS) or mainly third-line alternative (beyond SSAs and or everolimus) is recommended in morphologically progressive or high tumour burden advanced LC and ThCs [IV, B]